Knight Therapeutics Inc.

TSX:GUD Stok Raporu

Piyasa değeri: CA$570.5m

Knight Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Knight Therapeutics has a total shareholder equity of CA$762.8M and total debt of CA$51.0M, which brings its debt-to-equity ratio to 6.7%. Its total assets and total liabilities are CA$945.4M and CA$182.6M respectively. Knight Therapeutics's EBIT is CA$8.0M making its interest coverage ratio 41.5. It has cash and short-term investments of CA$157.5M.

Anahtar bilgiler

6.7%

Borç/özkaynak oranı

CA$50.95m

Borç

Faiz karşılama oranı41.5x
NakitCA$157.47m
EşitlikCA$762.80m
Toplam yükümlülüklerCA$182.56m
Toplam varlıklarCA$945.36m

Son finansal sağlık güncellemeleri

Recent updates

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Nov 17
Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GUD's short term assets (CA$360.6M) exceed its short term liabilities (CA$105.8M).

Uzun Vadeli Yükümlülükler: GUD's short term assets (CA$360.6M) exceed its long term liabilities (CA$76.7M).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GUD has more cash than its total debt.

Borcun Azaltılması: GUD's debt to equity ratio has increased from 0% to 6.7% over the past 5 years.

Borç Kapsamı: GUD's debt is well covered by operating cash flow (123.5%).

Faiz Kapsamı: GUD's interest payments on its debt are well covered by EBIT (41.5x coverage).


Bilanço


Sağlıklı şirketleri keşfedin